In this study, we demonstrated for the first time, that propofol, acting as an immunomodulating agent, exerts its anti-inflammatory role in sepsis by targeting Rab5a and thereby downregulating membrane TLR4 expression by macrophages. Here, TLR4 is linked to Sepsis.